Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Acrivon Therapeutics, Inc.

ACRV · Nasdaq · CIK 0001781174 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

34 Form 4 transaction lines observed in the same window
10 sales · 24 option, withholding, award, gift or other lines

Last qualifying purchase2026-01-14 · Blume-Jensen Peter; Masson Kristina · $82.3K

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesModerate
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Blume-Jensen Peter; Masson KristinaEVP - Business Operations; President and CEO
○○○▼▼
Miller MaryChief Legal Officer
○○▼▼▼
Peterson KatharineChief Accounting Officer
○○▼
Gamelin ErickChief Development Officer
○○▼
Devroe EricChief Operating Officer
○○▼
Levy Adam D.Chief Financial Officer
○▼
● Purchase▼ Sale○ Other

Showing the six most active owners; 9 additional owner(s) remain in Form 4 evidence.

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2026-01-14 · Blume-Jensen Peter; Masson Kristina.

Recent Form 4 activity

3Purchases
10Sales
40Other Form 4 lines
48SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING10 sale line(s) · context only
OTHER24 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-7.4%
3M
+11.8%
6M
+30.9%
12M
—

Volatility & liquidity

Volatility
89.5%
Beta
—
Avg daily value
—

Valuation

Market cap
—
P/E
—

Fundamentals

Profit margin
—
ROE
-69.2%
Industry
Biotechnology

Market data

Price data up to: 2026-10-04 · Price source: OpenBB/yfinance · From SEC filings: ROE · Fiscal year ended: 2025-12-31 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
1,616,727
Previous report
1,202,619
Avg daily volume
367,469
Days to cover
4.4

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-01-14Levy Adam D.Purchase (P)Common Stock8,832USD 1.70USD 15,014SEC filing ↗
2026-01-14Blume-Jensen Peter; Masson KristinaPurchase (P)Common Stock49,000USD 1.68USD 82,320SEC filing ↗
2026-01-13Devroe EricPurchase (P)Common Stock10,000USD 1.72USD 17,200SEC filing ↗
2024-04-11EDELMAN JOSEPH; PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTDPurchase (P)Common Stock2,353,000USD 8.50USD 20,000,500SEC filing ↗
2022-11-17Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M.Purchase (P)Common Stock3,389,500USD 12.50USD 42,368,750SEC filing ↗
2022-11-17Chione Ltd; Czernik Marcin; Hadjimichael Andreas; Nikolaou Anastasis; Smolokowski WiaczeslawPurchase (P)Common Stock400,000USD 12.50USD 5,000,000SEC filing ↗

Form 4 evidence

53 transaction lines in the latest 365-day window; 158 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-05Miller MarySale (S)Common Stock294USD 1.99USD 585SEC filing ↗
2026-08-31Levin MichaelaAward / grant (A)Common Stock30,000USD 0.00USD 0SEC filing ↗
2026-08-25Blume-Jensen Peter; Masson KristinaSale (S)Common Stock14,036USD 2.21USD 31,020SEC filing ↗
Show recent Form 4 evidence (30 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-05Miller MarySale (S)Common Stock294USD 1.99USD 585SEC filing ↗
2026-08-31Levin MichaelaAward / grant (A)Common Stock30,000USD 0.00USD 0SEC filing ↗
2026-08-25Blume-Jensen Peter; Masson KristinaSale (S)Common Stock14,036USD 2.21USD 31,020SEC filing ↗
2026-08-18Peterson KatharineSale (S)Common Stock101USD 2.01USD 203SEC filing ↗
2026-08-18Miller MarySale (S)Common Stock185USD 2.01USD 372SEC filing ↗
2026-08-18Gamelin ErickSale (S)Common Stock400USD 2.01USD 804SEC filing ↗
2026-08-18Devroe EricSale (S)Common Stock604USD 2.01USD 1,214SEC filing ↗
2026-08-18Blume-Jensen Peter; Masson KristinaSale (S)Common Stock1,713USD 2.01USD 3,443SEC filing ↗
2026-08-04Levy Adam D.Sale (S)Common Stock1,142USD 1.57USD 1,793SEC filing ↗
2026-07-21Miller MarySale (S)Common Stock573USD 1.76USD 1,008SEC filing ↗
2026-05-21Blume-Jensen Peter; Masson KristinaTax withholding (F)Common Stock13,729USD 1.79USD 24,575SEC filing ↗
2026-05-18TOMSICEK MICHAEL JOHNAward / grant (A)Common Stock9,366USD 0.00USD 0SEC filing ↗
2026-05-18Shacham SharonAward / grant (A)Common Stock9,366USD 0.00USD 0SEC filing ↗
2026-05-18Peterson KatharineAward / grant (A)Common Stock14,227USD 0.00USD 0SEC filing ↗
2026-05-18Palani SanthoshAward / grant (A)Common Stock9,366USD 0.00USD 0SEC filing ↗
2026-05-18Mirza Mansoor RazaAward / grant (A)Common Stock38,817USD 0.00USD 0SEC filing ↗
2026-05-18Miller MaryAward / grant (A)Common Stock49,830USD 0.00USD 0SEC filing ↗
2026-05-18Magovcevic-Liebisch IvanaAward / grant (A)Common Stock9,366USD 0.00USD 0SEC filing ↗
2026-05-18Levy Adam D.Award / grant (A)Common Stock46,167USD 0.00USD 0SEC filing ↗
2026-05-18Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M.Award / grant (A)Common Stock9,366USD 0.00USD 0SEC filing ↗
2026-05-18Gamelin ErickAward / grant (A)Common Stock38,584USD 0.00USD 0SEC filing ↗
2026-05-18DiRocco DerekAward / grant (A)Common Stock9,366USD 0.00USD 0SEC filing ↗
2026-05-18Devroe EricAward / grant (A)Common Stock72,981USD 0.00USD 0SEC filing ↗
2026-05-18Blume-Jensen Peter; Masson KristinaAward / grant (A)Common Stock252,801USD 0.00USD 0SEC filing ↗
2026-05-18BAUM CHARLES MAward / grant (A)Common Stock9,366USD 0.00USD 0SEC filing ↗
2026-05-14Peterson KatharineTax withholding (F)Common Stock99USD 1.92USD 190SEC filing ↗
2026-05-14Miller MaryTax withholding (F)Common Stock184USD 1.92USD 353SEC filing ↗
2026-05-14Gamelin ErickTax withholding (F)Common Stock404USD 1.92USD 776SEC filing ↗
2026-05-14Devroe EricTax withholding (F)Common Stock613USD 1.92USD 1,177SEC filing ↗
2026-05-14Blume-Jensen Peter; Masson KristinaTax withholding (F)Common Stock1,743USD 1.92USD 3,347SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerACRV
CIK0001781174
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history158 transaction lines from 2022-11-14 to 2026-10-05
6 P purchase lines · 20 S sale lines · 132 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.